New hope for hodgkin lymphoma: drug combo aims to boost transplant success

NCT ID NCT05180097

Recruiting now Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether combining two drugs, pembrolizumab and brentuximab vedotin, can better shrink or eliminate Hodgkin lymphoma compared to standard chemotherapy (GDP) before a stem cell transplant. About 84 adults with relapsed or refractory classical Hodgkin lymphoma will participate. The goal is to see if the new combo leads to higher complete response rates and better long-term outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab and brentuximab vedotin
What this could lead to: If successful, this combination could offer a more effective way to shrink or eliminate Hodgkin lymphoma before a stem cell transplant, potentially improving long-term outcomes.
What could go wrong: This is a small, early-phase trial with only 84 participants, so results may not apply to everyone. The drugs can cause serious side effects, and it's unknown if they will work better than standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN LYMPHOMA

Contacts and locations

Locations

Allan Blair Cancer Centre
RECRUITING

Regina, Saskatchewan, S4T 7T1, Canada
Arthur J.E. Child Comprehensive Cancer Centre
RECRUITING

Calgary, Alberta, T2N 5G2, Canada
Austin Hospital
RECRUITING

Heidelberg, Victoria, 3084, Australia
BCCA - Vancouver
RECRUITING

Vancouver, British Columbia, V5Z 4E6, Canada
CIUSSS de l'Estrie - Centre hospitalier
RECRUITING

Sherbrooke, Quebec, J1H 5N4, Canada
Concord Repatriation General Hospital
RECRUITING

Concord, New South Wales, 2139, Australia
Dr. H. Bliss Murphy Cancer Centre
RECRUITING

St. John's, Newfoundland and Labrador, A1B 3V6, Canada
Juravinski Cancer Centre at Hamilton Health Sciences
RECRUITING

Hamilton, Ontario, L8V 5C2, Canada
London Health Sciences Centre Research Inc.
RECRUITING

London, Ontario, N6A 5W9, Canada
Ottawa Hospital Research Institute
RECRUITING

Ottawa, Ontario, K1H 8L6, Canada
QEII Health Sciences Centre
RECRUITING

Halifax, Nova Scotia, B3H 1V7, Canada
Royal Adelaide Hospital
RECRUITING

Adelaide, South Australia, 5000, Australia
Shoalhaven Cancer Care Centre
RECRUITING

Nowra, New South Wales, 2541, Australia
Sir Charles Gairdner Hospital
RECRUITING

Perth, Western Australia, 6009, Australia
The Jewish General Hospital
RECRUITING

Montreal, Quebec, H3T 1E2, Canada
The Research Institute of the McGill University
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
University Health Network
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Wollongong Hospital
RECRUITING

Wollongong, New South Wales, 2500, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.